Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases

References

• Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007; 28:492–520.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Romagnani P, Brozzetti A, Santeusanio F, Serio M, Falorni A. Serum concentrations of the interferon-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia. 2003; 46:1020–1021.
   Google Scholar
• Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M. Chemokines and autoimmune thyroid diseases. Horm Metab Res. 2008; 40:361–368.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. Am J Pathol. 2002; 161:195–206.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab. 2004; 89:5496–5499.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol. 2006; 154:651–658.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg. 2006; 93:1226–1231.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab. 2007; 92:1485–1490.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009; 94:1803–1809.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: Modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2006; 91:614–620.
   PubMed Web of Science ®Google Scholar
• Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T, Li EK. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol. 2010; 37:257–264.
   Google Scholar
• Flytlie HA, Hvid M, Lindgreen E, Kofod-Olsen E, Petersen EL, Jørgensen A, Deleuran M, Vestergaard C, Deleuran B. Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Cytokine. 2010; 49:24–29.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, Park HY, Pflugfelder SC. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci. 2010; 51:643–650.
   PubMed Web of Science ®Google Scholar
• Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009; 8:379–383.
   PubMed Web of Science ®Google Scholar
• Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum. 2009; 60:3098–3107.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis—a longitudinal study. Rheumatology (Oxford). 2008; 47:45–49.
   PubMed Web of Science ®Google Scholar
• Punzi L, Betterle C. Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine. 2004; 71:275–283.
   PubMed Web of Science ®Google Scholar
• Soy M, Guldiken S, Arikan E, Altun BU, Tugrul A. Frequency of rheumatic diseases in patients with autoimmune thyroid disease. Rheumatol Int. 2007; 27:575–577.
   PubMed Web of Science ®Google Scholar
• Weetman TA. 2005. Chronic autoimmune thyroiditis. In: Braverman LE, Utiger RD. editors. Werner & Ingbar's The thyroid: A fundamental & clinical text. Philadelphia, PA: Lippincott Williams & Wilkins701–713.
   Google Scholar
• Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010; 123:183e1–183e9.
   Google Scholar
• Lazúrová I, Benhatchi K, Rovenský J, Kozáková D, Wagnerová H, Tajtáková M, Shoenfeld Y, Macejova Z. Autoimmune thyroid disease and autoimmune rheumatic disorders: A two-sided analysis. Ann N Y Acad Sci. 2009; 1173:211–216.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, Panicucci E, Neri R, Bombardieri S. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism. 2010; 59:896–900.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity. 2008; 41:537–542.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Ferrannini E. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol. 2008; 35:1809–1811.
   Google Scholar
• Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in patients with thyroid disease. Clin Endocrinol. 2003; 59:162–167.
   PubMedGoogle Scholar
• Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann NY Acad Sci. 2009; 1173:310–317.
   PubMed Web of Science ®Google Scholar
• Cakir M. 2010. Graves' disease. In: Cakir M. editors. Differential diagnosis of hyperthyroidism, endocrinology research and clinical developments series. New York: Nova Science Publishers1–14.
   Google Scholar
• Gardner DF. 2005. The neuromuscular system and brain in hypothyroidism. In: Braverman LE, Utiger RD. editors. Werner & Ingbar's the thyroid: A fundamental & clinical text. Philadelphia, PA: Lippincott Williams & Wilkins836–840.
   Google Scholar
• Rodolico C, Toscano A, Benvenga S, Mazzeo A, Bartolone S, Bartolone L, Girlanda P, Monici MC, Migliorato A, Trimarchi F, Vita G. Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid. 1998; 8:1033.
   Google Scholar
• Gardner DF. 2005. The neuromuscular system and brain in thyrotoxicosis. In: Braverman LE, Utiger RD. editors. Werner & Ingbar's the thyroid: A fundamental & clinical text. Philadelphia, PA: Lippincott Williams & Wilkins637–643.
   Google Scholar
• Manganelli P, Pavesi G, Salaffi F. Bilateral carpal tunnel syndrome in Graves' disease. Z Rheumatol. 1987; 46:34–35.
   Google Scholar
• Beard L, Kumar A, Estep HL. Bilateral carpal tunnel syndrome caused by Graves' disease. Arch Intern Med. 1985; 145:345–346.
   Google Scholar
• Uchiyama S, Itsubo T, Nakamura K, Kato H, Yasutomi T, Momose T. Current concepts of carpal tunnel syndrome: Pathophysiology, treatment, and evaluation. J Orthop Sci. 2010; 15:1–13.
   PubMedGoogle Scholar
• Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I. Prevalence of carpal tunnel syndrome in a general population. JAMA. 1999; 282:153–158.
   PubMed Web of Science ®Google Scholar
• Nakamichi K, Tachibana S. Histology of the transverse carpal ligament and flexor tenosynovium in idiopathic carpal tunnel syndrome. J Hand Surg [Am]. 1998; 23:1015–1024.
   PubMedGoogle Scholar
• Fuchs PC, Nathan PA, Myers LD. Synovial histology in carpal tunnel syndrome. J Hand Surg [Am]. 1991; 16:753–758.
   Google Scholar